vs
ANI PHARMACEUTICALS INC（ANIP）与六旗（FUN）财务数据对比。点击上方公司名可切换其他公司
ANI PHARMACEUTICALS INC的季度营收约是六旗的1.1倍（$247.1M vs $225.6M），ANI PHARMACEUTICALS INC净利率更高（11.1% vs -119.0%，领先130.2%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 11.7%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
六旗娱乐是总部位于美国北卡罗来纳州夏洛特的游乐园运营企业，由雪松会与原六旗公司于2024年7月1日对等合并而成，是全球最大的区域性游乐园运营商。旗下共运营42个场地，包含27座游乐园、15座水上乐园，配套9处 onsite 度假物业。
ANIP vs FUN — 直观对比
营收规模更大
ANIP
是对方的1.1倍
$225.6M
营收增速更快
ANIP
高出18.0%
11.7%
净利率更高
ANIP
高出130.2%
-119.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $225.6M |
| 净利润 | $27.5M | $-268.6M |
| 毛利率 | — | — |
| 营业利润率 | 14.1% | — |
| 净利率 | 11.1% | -119.0% |
| 营收同比 | 29.6% | 11.7% |
| 净利润同比 | 367.5% | -22.2% |
| 每股收益（稀释后） | $1.14 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPFUN
| Q1 26 | — | $225.6M | ||
| Q4 25 | $247.1M | $650.1M | ||
| Q3 25 | $227.8M | $1.3B | ||
| Q2 25 | $211.4M | $930.4M | ||
| Q1 25 | $197.1M | $202.1M | ||
| Q4 24 | $190.6M | — | ||
| Q3 24 | $148.3M | $1.3B | ||
| Q2 24 | $138.0M | $571.6M |
净利润ANIPFUN
| Q1 26 | — | $-268.6M | ||
| Q4 25 | $27.5M | $-92.4M | ||
| Q3 25 | $26.6M | $-1.2B | ||
| Q2 25 | $8.5M | $-99.6M | ||
| Q1 25 | $15.7M | $-219.7M | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | $111.0M | ||
| Q2 24 | $-2.3M | $55.6M |
毛利率ANIPFUN
| Q1 26 | — | — | ||
| Q4 25 | — | 91.4% | ||
| Q3 25 | — | 91.6% | ||
| Q2 25 | — | 91.3% | ||
| Q1 25 | — | 89.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 91.9% | ||
| Q2 24 | — | 90.7% |
营业利润率ANIPFUN
| Q1 26 | — | — | ||
| Q4 25 | 14.1% | -3.8% | ||
| Q3 25 | 15.9% | -83.7% | ||
| Q2 25 | 6.6% | 8.0% | ||
| Q1 25 | 13.3% | -158.9% | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | -13.8% | 19.5% | ||
| Q2 24 | 3.7% | 21.6% |
净利率ANIPFUN
| Q1 26 | — | -119.0% | ||
| Q4 25 | 11.1% | -14.2% | ||
| Q3 25 | 11.7% | -90.1% | ||
| Q2 25 | 4.0% | -10.7% | ||
| Q1 25 | 8.0% | -108.7% | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | 8.2% | ||
| Q2 24 | -1.7% | 9.7% |
每股收益（稀释后）ANIPFUN
| Q1 26 | — | — | ||
| Q4 25 | $1.14 | $-0.93 | ||
| Q3 25 | $1.13 | $-11.77 | ||
| Q2 25 | $0.36 | $-0.99 | ||
| Q1 25 | $0.69 | $-2.20 | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $-1.27 | $1.10 | ||
| Q2 24 | $-0.14 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $116.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $540.7M | $279.2M |
| 总资产 | $1.4B | $7.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPFUN
| Q1 26 | — | $116.5M | ||
| Q4 25 | $285.6M | $91.1M | ||
| Q3 25 | $262.6M | $70.7M | ||
| Q2 25 | $217.8M | $107.4M | ||
| Q1 25 | $149.8M | $61.5M | ||
| Q4 24 | $144.9M | — | ||
| Q3 24 | $145.0M | $89.7M | ||
| Q2 24 | $240.1M | $52.9M |
总债务ANIPFUN
| Q1 26 | — | — | ||
| Q4 25 | — | $5.2B | ||
| Q3 25 | — | $5.0B | ||
| Q2 25 | — | $5.3B | ||
| Q1 25 | — | $5.0B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $4.6B | ||
| Q2 24 | — | $2.3B |
股东权益ANIPFUN
| Q1 26 | — | $279.2M | ||
| Q4 25 | $540.7M | $549.8M | ||
| Q3 25 | $505.8M | $614.3M | ||
| Q2 25 | $436.8M | $1.8B | ||
| Q1 25 | $418.6M | $1.8B | ||
| Q4 24 | $403.7M | — | ||
| Q3 24 | $405.9M | $2.3B | ||
| Q2 24 | $455.8M | — |
总资产ANIPFUN
| Q1 26 | — | $7.7B | ||
| Q4 25 | $1.4B | $7.8B | ||
| Q3 25 | $1.4B | $7.9B | ||
| Q2 25 | $1.3B | $9.5B | ||
| Q1 25 | $1.3B | $9.2B | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.3B | $9.4B | ||
| Q2 24 | $920.8M | $2.3B |
负债/权益比ANIPFUN
| Q1 26 | — | — | ||
| Q4 25 | — | 9.40× | ||
| Q3 25 | — | 8.16× | ||
| Q2 25 | — | 2.97× | ||
| Q1 25 | — | 2.75× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.95× | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | — |
| 自由现金流经营现金流 - 资本支出 | $29.1M | — |
| 自由现金流率自由现金流/营收 | 11.8% | — |
| 资本支出强度资本支出/营收 | 0.5% | — |
| 现金转化率经营现金流/净利润 | 1.10× | — |
| 过去12个月自由现金流最近4个季度 | $171.4M | — |
8季度趋势，按日历期对齐
经营现金流ANIPFUN
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $-37.7M | ||
| Q3 25 | $44.1M | $356.2M | ||
| Q2 25 | $75.8M | $187.0M | ||
| Q1 25 | $35.0M | $-178.0M | ||
| Q4 24 | $15.9M | — | ||
| Q3 24 | $12.5M | $337.4M | ||
| Q2 24 | $17.4M | — |
自由现金流ANIPFUN
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | $-109.3M | ||
| Q3 25 | $38.0M | $256.2M | ||
| Q2 25 | $71.8M | $18.8M | ||
| Q1 25 | $32.5M | $-318.0M | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | $227.7M | ||
| Q2 24 | $13.0M | — |
自由现金流率ANIPFUN
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | -16.8% | ||
| Q3 25 | 16.7% | 19.4% | ||
| Q2 25 | 34.0% | 2.0% | ||
| Q1 25 | 16.5% | -157.4% | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | 16.9% | ||
| Q2 24 | 9.4% | — |
资本支出强度ANIPFUN
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 11.0% | ||
| Q3 25 | 2.7% | 7.6% | ||
| Q2 25 | 1.9% | 18.1% | ||
| Q1 25 | 1.3% | 69.3% | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | 8.1% | ||
| Q2 24 | 3.2% | — |
现金转化率ANIPFUN
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.04× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
FUN
| In-park admissions revenues | $113.4M | 50% |
| In-park product revenues | $89.0M | 39% |
| Out-of-park revenues | $28.8M | 13% |
